Over the last five years, the landscape of AML therapy in older patients with AML has moved from uniform approaches toward more personalized therapy based on molecularly defined subtypes that benefit from target-directed therapy. Favorable results obtained with the synergistic combination venetoclax/HMA are currently opening a new active treatment research era by adding other specific drugs to this backbone regimen.
Xavier, Thomas (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: